Roivant Sciences Ltd. ROIV

ROIV Quotes by TradingView
Institutional shares held 507 Million
1.26M calls
2.52M puts
Total value of holdings $5.71B
$14.2M calls
$28.3M puts
Market Cap $7.86B
704,382,976 Shares Out.
Institutional ownership 71.93%
# of Institutions 316

Quarterly Institutional Activity in ROIV

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding ROIV

View all
View all

Latest Institutional Activity in ROIV

Top Purchases

Q4 2024
Zweig Di Menna Associates LLC Shares Held: 99.5K ($1.11M)
99.5K Shares purchased
New Holding
Q4 2024
Nordea Investment Management Ab Shares Held: 283K ($3.16M)
52K Shares purchased
22.54% Added
Q4 2024
Impact Partnership Wealth, LLC Shares Held: 18.8K ($209K)
18.8K Shares purchased
New Holding
Q4 2024
Penn Davis Mcfarland Inc Shares Held: 1.65M ($18.4M)
16.8K Shares purchased
1.03% Added
Q4 2024
Everence Capital Management Inc Shares Held: 13.7K ($153K)
13.7K Shares purchased
New Holding
View All Buyers

Top Sells

Q4 2024
Bts Asset Management, Inc. Shares Held: 38.7K ($432K)
268 Shares sold
0.69% Reduced
Q4 2024
Toth Financial Advisory Corp Shares Held: 150 ($1.67K)
120 Shares sold
44.44% Reduced
Q4 2024
Crossmark Global Holdings, Inc. Shares Held: 20.5K ($229K)
46 Shares sold
0.22% Reduced
Q4 2024
Fny Investment Advisers, LLC Shares Held: 11.5K ($129K)
10 Shares sold
0.09% Reduced
Q3 2024
Viking Global Investors LP Shares Held: 54.1M ($604M)
15.1M Shares sold
21.77% Reduced
View All Sellers

About ROIV

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Chart by TradingView
ROIV Fundamental Data by TradingView

Insider Transactions at ROIV

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Jan 21 2025
Eric Venker President & COO
SELL
Open market or private sale
Direct
100,000 -12.02%
$1,100,000 $11.28 P/Share
Jan 21 2025
Eric Venker President & COO
BUY
Exercise of conversion of derivative security
Direct
100,000 +10.73%
$300,000 $3.85 P/Share
Jan 20 2025
Matthew Gline CEO
SELL
Payment of exercise price or tax liability
Direct
11,623 -0.07%
$127,853 $11.15 P/Share
Jan 20 2025
Eric Venker President & COO
SELL
Payment of exercise price or tax liability
Direct
8,682 -1.17%
$95,502 $11.15 P/Share
Jan 20 2025
Rakhi Kumar Chief Accounting Officer
SELL
Payment of exercise price or tax liability
Direct
1,057 -0.52%
$11,627 $11.15 P/Share
Dec 30 2024
Eric Venker President & COO
SELL
Open market or private sale
Direct
177,704 -19.34%
$1,954,744 $11.54 P/Share
Dec 30 2024
Eric Venker President & COO
BUY
Exercise of conversion of derivative security
Direct
250,000 +21.39%
$750,000 $3.85 P/Share
Dec 28 2024
Richard Pulik CFO
SELL
Payment of exercise price or tax liability
Direct
1,896 -0.69%
$20,856 $11.8 P/Share
Dec 27 2024
Eric Venker President & COO
SELL
Open market or private sale
Direct
176,900 -20.92%
$1,945,900 $11.82 P/Share
Dec 27 2024
Eric Venker President & COO
BUY
Exercise of conversion of derivative security
Direct
250,000 +22.82%
$750,000 $3.85 P/Share
Dec 26 2024
Mayukh Sukhatme Pres&Chief Investment Officer
BUY
Exercise of conversion of derivative security
Direct
689,495 +3.41%
$2,068,485 $3.85 P/Share
Dec 24 2024
Mayukh Sukhatme Pres&Chief Investment Officer
SELL
Open market or private sale
Direct
185,946 -0.98%
$2,231,352 $12.0 P/Share
Dec 24 2024
Mayukh Sukhatme Pres&Chief Investment Officer
BUY
Exercise of conversion of derivative security
Direct
185,946 +0.97%
$557,838 $3.85 P/Share
Dec 23 2024
Mayukh Sukhatme Pres&Chief Investment Officer
SELL
Open market or private sale
Direct
10,796 -0.06%
$129,552 $12.0 P/Share
Dec 23 2024
Mayukh Sukhatme Pres&Chief Investment Officer
BUY
Exercise of conversion of derivative security
Direct
10,796 +0.06%
$32,388 $3.85 P/Share
Dec 20 2024
Matthew Gline CEO
SELL
Payment of exercise price or tax liability
Direct
10,945 -0.06%
$120,395 $11.57 P/Share
Dec 20 2024
Eric Venker President & COO
SELL
Open market or private sale
Direct
100,000 -14.38%
$1,100,000 $11.49 P/Share
Dec 20 2024
Eric Venker President & COO
BUY
Exercise of conversion of derivative security
Direct
100,000 +12.57%
$300,000 $3.85 P/Share
Dec 20 2024
Eric Venker President & COO
SELL
Payment of exercise price or tax liability
Direct
10,945 -1.8%
$120,395 $11.57 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
41.6M Shares
From 14 Insiders
Grant, award, or other acquisition 36.4M shares
Exercise of conversion of derivative security 5.22M shares
Sell / Disposition
137M Shares
From 26 Insiders
Payment of exercise price or tax liability 934K shares
Other acquisition or disposition 126M shares
Open market or private sale 10.2M shares
Grant, award, or other acquisition 38.7K shares

Track Institutional and Insider Activities on ROIV

Follow Roivant Sciences Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ROIV shares.

Notify only if

Insider Trading

Get notified when an Roivant Sciences Ltd. insider buys or sells ROIV shares.

Notify only if

News

Receive news related to Roivant Sciences Ltd.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ROIV